Sight Sciences’ management is scheduled to present on Thursday, February 27, 2025, at 7:15 am PT / 10:15 am ET. Interested parties may access a live and archived webcast of the fireside chat on the ...

QLS‑111 is a novel topical formulation using Qlaris Bio’s ATP-sensitive potassium channel modulator platform. QLS-111 lowers ...

nottingham.ac.uk Background The trabecular meshwork (TM) located at the angle of the anterior chamber of the eye contributes to aqueous drainage. A novel layer in the posterior part of the human ...

Iantrek has reached an exciting milestone as we transition from development of our bio-interventional technologies to ...

For LOC102551819, there was almost no expression in the AH and trabecular meshwork in patients with glaucoma but high expression was observed in the iris. Conclusion: Our research proposes potential ...

Himani Goyal, MD, takes glaucoma care to the next level by embracing advancements that extend beyond traditional treatment ...

Indentation gonioscopy and dark room SS-OCT were performed. Gonioscopic angle closure was defined as non-visibility of the posterior trabecular meshwork in ≥180° of the angle. For each subject, all ...

Qlaris Bio, Inc., a clinical-stage biotechnology company targeting unmet needs in debilitating ophthalmic diseases, today announced positive topline results from two U.S. Phase II clinical trials ...

Qlaris Bio is seeing double when it comes to phase 2 wins for its eye drug, hitting the primary endpoints in trials that both spanned primary open angle glaucoma (POAG) and ocular hypertension (OHT).

We present a case of unilateral, secondary open-angle glaucoma due to an underlying diffuse iris melanoma. The patient was referred by his ophthalmologist with uncontrolled, elevated intraocular ...